Warning: There are an increasing number of fraudulent websites and emails that impersonate FENS. We would like to alert all our members, delegates, and exhibitors to possible scams. We strongly advise you to use only the official FENS online registration and accommodation for your bookings, and not to trust emails offering attendee lists.

MC04 - What is the mode of action of serotonin psychedelics in brain disorders? - Organised by ‎European College of Neuropsychopharmacology (ECNP) (09:00-15:00)

Psychedelics such as psilocybin (‘magic mushrooms’), LSD and ayahuasca have lately gained renewed attention as novel therapeutics for neuropsychiatric disorders such as depression, anxiety, obsession and addiction. The experts will cover a spectrum of topics from basic neuroscience to novel neuroimaging techniques in studies of humans under influence of psychedelics.

Start

July 9, 2022

End

July 9, 2022

Address

Pavillion 7, Paris Expo Porte de Versailles   View map

Serotonin psychedelics (e.g., psilocybin, LSD and ayahuasca) have gained recent international attention as novel therapeutics for hard-to-treat neuropsychiatric disorders including depression, anxiety, obsession and addiction. The rapid development of large-scale clinical trials demands a comparable understanding of the brain mechanisms associated with and mediating the acute psychoactive as well as lasting clinical and behavioral effects of these drugs. This mini conference will address how the pharmacological profile of serotonergic psychedelics differ and the potential impact of such differences on the neurobiological mechanism of action. Preclinical methods to elucidate potential clinical effects of different classes of serotonin psychedelics are considered and the translational value of animal and human studies will be discussed. Relevant and unaddressed outcome measures of brain function and
underlying signaling pathways during both the acute experience state and lasting post-drug effects will also be addressed.

Moderators: Gitte M Knudsen, Denmark and Eero Castren, Finland.

Emma S J Robinson, UK – Investigating the neuropsychological effects of psychedelics and other rapid-acting antidepressants using a translational rodent model
Aslihan Selimbeyoglu, UK – Generating translational endpoints for psychedelic therapy development
Tomáš Páleníček, Czech Republic – Do animal studies with psychedelics have translational validity? Inputs from behavioural and pharmacoEEG experiments
Dino Lüthi, Switzerland – Pharmacology and toxicology of novel psychedelic phenethylamines, tryptamines, and lysergamides
Deborah Rudin, Switzerland – Preclinical pharmacological profiling as predictor for the clinical potency and effects of psychedelics
Patrick Fisher, Denmark – Neuroimaging effects of psychedelics in humans and perspectives for treatment of patients with major depression